BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 17429836)

  • 21. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee KH; Lee JH; Choi SJ; Lee JH; Seol M; Lee YS; Kim WK; Lee JS; Seo EJ; Jang S; Park CJ; Chi HS
    Leukemia; 2005 Sep; 19(9):1509-16. PubMed ID: 16034462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
    Yanada M; Sugiura I; Takeuchi J; Akiyama H; Maruta A; Ueda Y; Usui N; Yagasaki F; Yujiri T; Takeuchi M; Nishii K; Kimura Y; Miyawaki S; Narimatsu H; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
    Br J Haematol; 2008 Nov; 143(4):503-10. PubMed ID: 18986386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study.
    Delannoy A; Delabesse E; Lhéritier V; Castaigne S; Rigal-Huguet F; Raffoux E; Garban F; Legrand O; Bologna S; Dubruille V; Turlure P; Reman O; Delain M; Isnard F; Coso D; Raby P; Buzyn A; Caillères S; Darre S; Fohrer C; Sonet A; Bilhou-Nabera C; Béné MC; Dombret H; Berthaud P; Thomas X
    Leukemia; 2006 Sep; 20(9):1526-32. PubMed ID: 16838024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Acute lymphoblastic leukemia in elderly: prognosis and treatment].
    Thomas X; Tavernier E; Le QH
    Bull Cancer; 2004 Sep; 91(9):713-20. PubMed ID: 15544997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Sancho JM; Ribera JM; Xicoy B; Morgades M; Oriol A; Tormo M; del Potro E; Debén G; Abella E; Bethencourt C; Ortín X; Brunet S; Ortega-Rivas F; Novo A; López R; Hernández-Rivas JM; Sanz MA; Feliu E;
    Eur J Haematol; 2007 Feb; 78(2):102-10. PubMed ID: 17087744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: a 5-year follow up.
    Hess G; Meyer RG; Schuch B; Bechthold K; El-Kholy I; Huber C
    Am J Hematol; 2008 Mar; 83(3):178-84. PubMed ID: 17876770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients.
    Piccaluga PP; Malagola M; Amabile M; Rondoni M; Paolini S; Pane F; Russo D; Visani G; Baccarani M; Martinelli G
    Haematologica; 2004 Oct; 89(10):1269-71. PubMed ID: 15477218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89). Spanish Society of Hematology.
    Ribera JM; Ortega JJ; Oriol A; Fontanillas M; Hernández-Rivas JM; Brunet S; García-Conde J; Maldonado J; Zuazu J; Gardella S; Besalduch J; León P; Macià J; Domingo-Albós A; Feliu E; San Miguel JF
    Haematologica; 1998 Mar; 83(3):222-30. PubMed ID: 9573676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of imatinib mesylate as maintenance therapy in adults with acute lymphoblastic leukemia in first complete remission.
    Potenza L; Luppi M; Riva G; Marasca R; Martinelli S; Torelli G
    Haematologica; 2005 Sep; 90(9):1275-7. PubMed ID: 16154854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Additional chromosomal abnormalities and their prognostic significance in adult Philadelphia-positive acute lymphoblastic leukemia: with or without imatinib in chemotherapy.
    Li Y; Qiu L; Zou D; Zhao Y; Mi Y; Wang J
    Ann Hematol; 2009 Nov; 88(11):1069-77. PubMed ID: 19277658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute lymphoblastic leukemia in the elderly: The Edouard Herriot Hospital experience.
    Thomas X; Olteanu N; Charrin C; Lhéritier V; Magaud JP; Fiere D
    Am J Hematol; 2001 Jun; 67(2):73-83. PubMed ID: 11343378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Philadelphia chromosome-positive mixed phenotype acute leukemia in the imatinib era.
    Shimizu H; Yokohama A; Hatsumi N; Takada S; Handa H; Sakura T; Nojima Y
    Eur J Haematol; 2014 Oct; 93(4):297-301. PubMed ID: 24750307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prolonged survival with imatinib mesylate combined with chemotherapy and allogeneic stem cell transplantation in de novo Ph+ acute myeloid leukemia.
    Sun J; Wang Z; Luo Y; Tan Y; Allan DS; Huang H
    Acta Haematol; 2012; 127(3):143-8. PubMed ID: 22248505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10).
    Wassmann B; Gökbuget N; Scheuring UJ; Binckebanck A; Reutzel R; Gschaidmeier H; Hoelzer D; Ottmann OG;
    Ann Hematol; 2003 Nov; 82(11):716-20. PubMed ID: 14648032
    [No Abstract]   [Full Text] [Related]  

  • 35. Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.
    Wernstedt P; Brune M; Andersson PO; Gustavsson B; Stockelberg D; Wadenvik H
    Bone Marrow Transplant; 2002 Dec; 30(12):971-3. PubMed ID: 12476293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complete molecular remission in a patient with Philadelphia-chromosome positive acute myeloid leukemia after conventional therapy and imatinib.
    Jentsch-Ullrich K; Pelz AF; Braun H; Koenigsmann M; Mohren M; Wieacker P; Franke A
    Haematologica; 2004 May; 89(5):ECR15. PubMed ID: 15136244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival.
    Burke MJ; Trotz B; Luo X; Baker KS; Weisdorf DJ; Wagner JE; Verneris MR
    Bone Marrow Transplant; 2009 Jan; 43(2):107-13. PubMed ID: 18776928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005.
    Rives S; Estella J; Gómez P; López-Duarte M; de Miguel PG; Verdeguer A; Moreno MJ; Vivanco JL; Couselo JM; Fernández-Delgado R; Maldonado M; Tasso M; López-Ibor B; Lendínez F; López-Almaraz R; Uriz J; Melo M; Fernández-Teijeiro A; Rodríguez I; Badell I
    Br J Haematol; 2011 Sep; 154(5):600-11. PubMed ID: 21707583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imatinib: new indication. New indications, but not robust evidence.
    Prescrire Int; 2008 Jun; 17(95):91-4. PubMed ID: 18623899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of acute lymphoblastic leukemia in adults with seven-drug induction therapy and intensive consolidation with or without autologous stem cell transplantation followed by maintenance therapy. Experience of a single center].
    Doubek M; Mayer J; Korístek Z; Protivánková M; Brychtová Y; Oborilová A; Král Z; Klabusay M; Tomíska M; Buchtová I; Vorlícek J
    Cas Lek Cesk; 2002 Mar; 141(4):122-6. PubMed ID: 12046256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.